1. Home
  2. BMRA vs VIVS Comparison

BMRA vs VIVS Comparison

Compare BMRA & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

N/A

Current Price

$2.49

Market Cap

8.2M

Sector

Health Care

ML Signal

N/A

Logo VivoSim Labs Inc. Common Stock

VIVS

VivoSim Labs Inc. Common Stock

HOLD

Current Price

$2.39

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMRA
VIVS
Founded
1971
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
8.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BMRA
VIVS
Price
$2.49
$2.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.5K
46.1K
Earning Date
01-13-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,884,000.00
$140,000.00
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.92
52 Week Low
$2.08
$1.41
52 Week High
$10.16
$21.96

Technical Indicators

Market Signals
Indicator
BMRA
VIVS
Relative Strength Index (RSI) 52.29 53.51
Support Level $2.26 $2.11
Resistance Level $2.39 $2.40
Average True Range (ATR) 0.13 0.13
MACD 0.03 0.04
Stochastic Oscillator 76.53 74.70

Price Performance

Historical Comparison
BMRA
VIVS

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

About VIVS VivoSim Labs Inc. Common Stock

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: